

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/231565217>

Metallopeptidase Inhibitors of Tetanus Toxin: A Combinatorial Approach

ARTICLE in JOURNAL OF MEDICINAL CHEMISTRY · JANUARY 1999

Impact Factor: 5.45 · DOI: 10.1021/jm981066w

CITATIONS

43

READS

14

6 AUTHORS, INCLUDING:



Loïc Martin

Atomic Energy and Alternative Energies Com...

69 PUBLICATIONS 1,466 CITATIONS

SEE PROFILE



Serge Turcaud

Université René Descartes - Paris 5

44 PUBLICATIONS 1,283 CITATIONS

SEE PROFILE



Hervé Meudal

French National Centre for Scientific Research

33 PUBLICATIONS 616 CITATIONS

SEE PROFILE



Bernard P. Roques

Université René Descartes - Paris 5

239 PUBLICATIONS 8,361 CITATIONS

SEE PROFILE

Metallopeptidase Inhibitors of Tetanus Toxin: A Combinatorial Approach

Loïc Martin, Fabrice Cornille, Serge Turcaud, Hervé Meudal, Bernard P. Roques,* and Marie-Claude Fournié-Zaluski

Département de Pharmacochimie Moléculaire et Structurale, U266 INSERM, UMR 8600 CNRS, UFR des Sciences Pharmaceutiques et Biologiques, 4, Avenue de l'Observatoire, 75270 Paris Cedex 06, France

Received July 31, 1998

The bacterial protein tetanus toxin (TeNt), which belongs to the family of zinc endopeptidases, cleaves synaptobrevin, an essential synaptic protein component of the neurotransmitter exocytosis apparatus, at a single peptide bond (Gln⁷⁶–Phe⁷⁷). This protease activity is a particularly attractive target for designing potent and selective synthetic inhibitors as a possible drug therapy for tetanus. β -Aminothiols mimicking Gln⁷⁶ of synaptobrevin have been previously shown to inhibit the tetanus neurotoxin enzymatic activity in the 35–250 μ M range. These compounds have now been modified to interact with S' subsites of the TeNt active site, with the aim of increasing their inhibitory potencies. Combinatorial libraries of pseudotriptides, containing an ethylene sulfonamide or an *m*-sulfonamidophenyl moiety as the P₁ side chain and natural amino acids in P₁' and P₂' positions, were synthesized. The best inhibitory activity was observed with Tyr and His as P₁' and P₂' components, respectively. This led to new inhibitors of TeNt with K_i values in the 3–4 μ M range. These molecules are the most potent inhibitors of TeNt described so far.

Introduction

Tetanus neurotoxin (TeNt) is a 150-kDa protein produced by the anaerobic bacillus *Clostridium tetani*, which causes the lethal spastic paralysis of tetanus by blockade of inhibitory neurotransmitter release at central synapses.^{1,2} It is a member of the clostridial neurotoxin family, which includes seven botulinum neurotoxins responsible for the flaccid paralysis of botulism.^{1,2} TeNt is composed of two polypeptide chains joined by a single interchain disulfide bond.¹ The heavy chain (100 kDa) participates in binding to the nerve terminals, internalization, retrograde axonal transport, and membrane translocation of the toxic light chain (50 kDa) into the neuronal cytosol.^{1,3} The light chain, after reduction of the disulfide bridge, is responsible for the inhibition of neurotransmitter release.¹

TeNt belongs to the thermolysin family of Zn²⁺ metallopeptidases that contains the HEXxH consensus sequence,^{4–6} in which the two histidines are involved in zinc chelation whereas the glutamate is involved in catalysis.⁷ This has been shown by site-directed mutagenesis experiments^{8,9} and recently confirmed by the crystal structure determination of botulinum neurotoxin type A (BoNt/A).¹⁰ TeNt has been shown to cleave a single 116-residue protein, VAMP/synaptobrevin, at the Gln⁷⁶–Phe⁷⁷ peptide bond¹¹ (Figure 1). This protein is an essential component of the neuro-exocytosis apparatus,^{12–14} and its cleavage by TeNt leads to the blockade of inhibitory neurotransmitter release.¹¹ Such a narrow specificity, not common for other zinc peptidases,⁶ has been recently explained by a cooperative mechanism, involving the binding to TeNt of synaptobrevin domains distal from the cleavage site for subse-

quent activation of proteolysis.^{15–17} This probably explains why potent inhibitors of well-known zinc metallopeptidases such as captopril, thiorphan, or phosphoramidon have a weak inhibitory activity on TeNt, in the 10 mM range in vitro^{18,19} or ex vivo.^{20,21} As no efficient drug therapy is yet available for tetanus or botulism, we identified the zinc-dependent metallopeptidase activity of tetanus neurotoxin as a good target.

The best-described inhibitory potencies for TeNt were obtained recently²² with glutaminethiol **1** (K_i = 250 \pm 35 μ M) and its sulfonamide analogues **2** (K_i = 100 \pm 5 μ M) and **3** (K_i = 35 \pm 5 μ M), expected to interact with the S₁ subsite of TeNt (Figure 2A). To improve the potency of these compounds, we report here the synthesis of analogues able to interact with additional subsites of the TeNt catalytic site. Given the critical importance of the primary amino group in compounds **1–3** for TeNt recognition,²² these molecules were extended in order to interact with S' subsites (Figure 2B). To have access to such compounds, the synthesis of the new fully protected β -amino- α -sulfanyl acids (Figure 2C) corresponding to synthons A, B, and C was achieved. These synthons were used in the solid-phase peptide synthesis of pseudotriptides. The screening of a combinatorial library of such analogues toward TeNt allowed the preference of the S₁' and S₂' subsites to be determined.

Chemistry

Synthesis of Synthons A and B. The commercially available Boc-L-Gln(Trt)-OH (**4a**) and the (2*S*)-4-(*tert*-butylsulfamoyl)-2-(Cbz-amino)butanoic acid (**4b**) prepared from the Z-L-homocysteine as previously described²² were first homologated by the Arndt-Eistert reaction as described in Scheme 1.²³ Their free acid functions, activated as mixed anhydride derivatives,

* To whom correspondence should be addressed. Tel: (33) 01-43-25-50-45. Fax: (33) 01-43-26-69-18.




Figure 1. (A) Schematic representation of VAMP/synaptobrevin II. TMR indicates the transmembrane region and IR the intravesicular region. The cleavage site Gln⁷⁶–Phe⁷⁷ is indicated by the arrow. Domains 27–55 and 82–93 represent respectively the acidic and basic clusters whose binding to tetanus neurotoxin is required to switch on its proteolytic activity.¹⁶ (B) Human synaptobrevin II sequence surrounding the scissible bond. The side chains of the different synaptobrevin residues are putatively interacting with subsites of the catalytic domain of TeNT designated S₁ to S₆ on the left of the cleavage bond and S'₁ to S'₅ on the right.





Figure 2. (A) β -Aminothiols bearing carboxamide or sulfonamide functionalities on aliphatic or aromatic side chains endowed with inhibitory activities against tetanus neurotoxin. (B) Extension of these β -aminothiols toward S' subsites of TeNT. (C) Protected synthons required for the synthesis of such types of molecules.

were converted into the corresponding diazo ketones by action of diazomethane. These diazo ketones underwent the Wolff rearrangement in methanol with silver benzoate as a catalyst to afford the β -amino esters **5a** and **5b** (84% and 95% yields, respectively). The carbanions of these β -amino esters, formed by action of lithium diisopropylamide, were sulfenylated by the asymmetric 4-methoxybenzyl 2,4-dinitrophenyl disulfide according to the recent improvements reported in the synthesis of α -sulfenylated β -amino acids²⁴ (43% and 54% yields, respectively). The ester functions of resulting **6a** and


Scheme 1. Synthesis of Synthon A and Synthon B^a



^a (a) $iBuOCOC(=O)Cl$, NMM, CH_2N_2 ; (b) $BzOAg$, NEt_3 , MeOH; (c) LDA, 4-methoxybenzyl 2,4-dinitrophenyl disulfide; (d) MeOH, NaOH.

6b were hydrolyzed by 1 M NaOH to yield the final synthons A and B, which were obtained as racemates on the C2 carbon bearing the thiol group.

Synthesis of Synthon C. Scheme 2 shows the pathway used in the synthesis of the *meta*-substituted sulfonamide analogues of β -aminophenylalanine (synthon C) obtained as a mixture of two diastereomers (2*SR*,3*S*) or as a pure diastereomer (2*S*,3*S*). The commercially available 3-(chlorosulfonyl)benzoic acid (**7**) was transformed into the *tert*-butylsulfonamide derivative **8** by *tert*-butylamine treatment (78% yield) and then transformed into the corresponding substituted benzaldehyde via a reduction of the free carboxylic group into the corresponding alcohol **9**²⁵ (90% yield), subsequently oxidized by the Swern method to afford the aldehyde **10**²⁶ (96% yield). Compound **10** was then converted by a Horner–Wadsworth–Emmons olefination²⁷ into an acrylate intermediate **11** (85% yield). A Michael addition performed on compound **11** with the homochiral lithium (*S*)-benzyl(α -methylbenzyl)amide yielded the β -aminophenylalanine derivative (α ,**S**,**3R**)-**12a**²⁸ with an enantiomeric excess > 99% (87% yield). Hydrogenolysis under 5 atm in ethyl acetate in the presence of Boc_2O ²⁸ afforded the *N*-Boc-protected ethyl ester β -aminophenylalanine analogue (**3R**)-**13a** (85% yield). The formation of the α -carbanion of **13a** with lithium diisopropylamide (LDA) followed by treatment with 4-methoxybenzyl 2,4-dinitrophenyl disulfide yielded

Scheme 2. Synthesis of Synthon C^a

the diastereomer (**2S,3S**)-**14a** ($2S,3S/2R,3S = 85/15$). The hydrolysis of the ethyl ester by bis(tributyltin)oxide (BBTO) gave the synthon C (**2S,3S**) without further racemization (70% yield), while its hydrolysis by 1 M NaOH in MeOH overnight at room temperature gave a 50/50 mixture of the two diastereomers ($2R,3S$ and $2S,3S$). To obtain the two other diastereomers ($2R,3R$ and $2S,3R$), the homochiral lithium (R)-benzyl(α -methylbenzyl)amide was used in the same synthetic pathway instead of the S isomer. In addition, the 2,4-dimethoxybenzylthio 4-methylphenylsulfonate was used as sulfenylating agent to obtain **14c** and **14d** with a thiol protected by a dimethoxybenzyl group.³⁰ The HPLC separation of both diastereomers after TFA deprotection and before HF cleavage becomes easier in this case than with the monomethoxybenzyl protecting group.

Syntheses of Substrate Mimics Derived from Compound 1. The syntheses of the thiol peptide derivatives spanning the various subsites defined as S_1 , S_1' , S_2' , S_3' , and S_4' of the tetanus toxin catalytic domain were performed by solid-phase peptide synthesis using synthon A, the protected amino acids corresponding to Phe, Glu, Thr, Ser, and the Fmoc/ $t\text{Bu}$ strategy on Wang/HMP resin (Figure 3).³¹ Cleavage from the solid support and deprotection of side-chain-protecting groups were achieved by using trifluoroacetic acid in the presence of scavengers.³² This was followed by a final HF treatment³³ in order to obtain the various carboxamide thiols (**15**–**18**) which were then purified by reverse-phase HPLC.

Synthesis of Combinatorial Libraries of Thiol-Containing Inhibitors. A pseudotripeptide library, corresponding to 19 mixtures of thiol-containing peptides of formula (synthon B)- $\text{AA}'_{1x}\text{AA}'_{2x}$, where AA'_{1x} and AA'_{2x} represent the 19 different natural amino acids (Cys omitted), was obtained by solid-phase peptide synthesis on 2-chlorotrityl chloride resin³⁴ by using a




Figure 3. (A) Synaptobrevin sequence ⁷⁶QFETS in interaction with S and S' subsites of tetanus neurotoxin. (B) Inhibition constants of pseudopeptides mimicking the synaptobrevin sequence ⁷⁶QF (**15**), ⁷⁶QFE (**16**), ⁷⁶QFET (**17**), and ⁷⁶QFETS (**18**), respectively.

previously described protocol^{35,36} (Figure 4). The Divide/Couple/Recombine method³⁷ was used to synthesize these 19 sublibraries. A first amino acid mixture was prepared by combining the 19 different amino acids linked to the 2-chlorotrityl resin (Cys was omitted). This homogenized mixture is then split into 19 identical samples to which a known amino acid is coupled. This gives rise to 19 different mixtures, each of them containing 19 different dipeptides. The next step is the coupling of synthon B in each sample allowing the synthesis of 19 mixtures containing 19 couples of diastereomers. The 19 fractions of peptidyl resin were then cleaved from the resin by using a dichloromethane/trifluoroethanol mixture³⁸ (8/2). The deprotection of the TFA-labile protecting groups was achieved by using trifluoroacetic acid,³² and the final deprotection step used to hydrolyze the benzylcarbamate group and the 4-methoxybenzyl group was performed with anhydrous hydrogen fluoride.³³ The 19 freeze-dried sublibraries were soluble in water at 1 mM. Electrospray mass spectra and quantitative amino acid analysis showed in each case a correct mass distribution and a good stoichiometry in the S_2' position, respectively (data not shown).

A second library corresponding to the parallel synthesis of 19 mixtures of two diastereomers of pseudotripeptides of formula (synthon B)-Tyr-AA'_{2x} was achieved on 2-chlorotrityl chloride resin with the same protocol described above.

Syntheses of Inhibitors Derived from the Libraries. The two diastereomers **19a** and **19b** (Figure 5A), issued from the best mixtures of the library (tyrosyl in S_1' and histidyl in S_2'), were purified and separated by RP-HPLC. To assign unambiguously the absolute configuration of the C2 carbon bearing the thiol group, the solid-phase synthesis of the diastereomer **19b** alone was performed by successive coupling of Fmoc-protected histidine, tyrosine, and the optically pure synthon B (**2S,3S**) obtained by hydrolysis of the methyl ester of **6b** by BBTO. Cleavage from the resin and side-chain deprotection were achieved with the same protocol described for the libraries.




Figure 4. Histograms representing the percentage of inhibition obtained with 38 mixtures of pseudotripeptides derived from the β -aminothiol **2** (Figure 1) on tetanus neurotoxin zinc endoprotease activity. The general formula of these mixtures of compounds is given above the histogram. (A) Each mixture differs by a natural amino acid (except Cys) putatively interacting in S₁' which is represented as a one-letter code on the abscissa. A stoichiometric amount of each natural amino acid (except Cys) is present in S₂'. These mixtures were tested at 33 μ M on TeNt. (B) A same tyrosyl residue is present in S₁'. Each mixture differs by the residue present in S₂' which corresponds to a natural amino acid (except Cys) indicated as a one-letter code on the abscissa. These mixtures were tested at 25 μ M on TeNt.

Finally, synthon B (2*RS*,3*S*), and synthons C (2*RS*,3*S* and 2*RS*,3*R*) were coupled independently with the protected dipeptide H-Tyr(tBu)-His(Trt)-NHBzl. After deprotection by trifluoroacetic acid,³² the resulting compounds were purified at this step by semipreparative HPLC in order to separate the couples of diastereomers and treated by anhydrous hydrogen fluoride³³ to afford compounds **20a**, **20b** (Figure 5A), **21a**, **21b**, **21c**, and **21d** (Figure 5B), respectively. To assign unambiguously the absolute configuration of the C2 carbon bearing the thiol, the syntheses of compounds **20b**, **21b**, and **21c** were achieved independently by using optically pure synthon B (2*S*,3*S*), synthon C (2*S*,3*S*), and synthon C (2*R*,3*R*). The ¹H NMR chemical shifts as well as the HPLC retention times of these compounds were compared to those of the corresponding




Figure 5. (A) Inhibition constants values of pseudotripeptides derived from the β -aminothiol **2** (Figure 2). The different absolute configurations of the C2 and C3 carbons of the β -amino acid synthon are indicated. (B) Inhibition constant values of pseudotripeptides derived from the β -aminothiol **3** (Figure 2). The different absolute configurations of the C2 and C3 carbons of the β -amino acid synthon are indicated.

couples of diastereomers in order to assign the absolute configuration of the chiral centers.

Biological Results

The various pseudopeptides **15–18** were tested on TeNt metalloprotease activity in vitro.³⁹ The results are summarized in Figure 3. As compared to glutamethiol **1**, which had a K_i of 250 ± 35 μ M (Figure 2A), the four compounds **15–18** exhibited increased inhibitory potencies with K_i values in the 80–100 μ M range (Figure 3). Nevertheless, no significant difference was observed among them. Therefore, the pseudotripeptide was selected as a scaffold to investigate the S₁' and S₂' subsites of tetanus neurotoxin and to try increase the inhibitory potency. These molecules represent a good compromise in terms of size to generate structured diversity for exploring the S' subsites.

For this purpose, a combinatorial library of pseudotripeptides derived from the sulfonamide analogue **2** was used. The results are summarized in Figure 4. Among the different mixtures corresponding to known amino acids putatively interacting with S₁' (Figure 4A), a significant preference for a tyrosyl residue (52% inhibition) was observed. Nevertheless, no great differences were observed for the other mixtures, with a 40% inhibition for Val, Asn, Gln, Gly, and Lys and from 15% to 35% inhibition for the others. Surprisingly, a Phe side

chain, mimicking the natural substrate synaptobrevin in the P_1' position, was not among the best inhibitors (30% inhibition). Although no clear preference for the S_1' subsite of TeNt was observed, the apparent best P_1' component, Tyr, was used to develop a second library of these pseudotripeptides possessing different natural amino acids in S_2' . This library, composed of mixtures of two diastereomers, was screened against TeNt metallopeptidase activity (Figure 4B). The best residues issued from this screening were His and Ile (60% and 55% inhibition, respectively). The other analogues demonstrated an inhibitory potency in the 30–50% range (except Gly, 15%). However, no great subsite specificity could be defined, even if a slight preference for aromatic or aliphatic side chains (His, Ile, Tyr, Val) was observed.

The best compound issued from both libraries, corresponding to a tyrosyl residue in S_1' and a histidyl residue in S_2' , was purified and fully characterized. The corresponding two diastereomers **19a** and **19b** (Figure 5A) were separated by HPLC and screened independently on TeNt proteolytic activity. The compound **19a** corresponding to the *2R,3S* absolute configuration was the best with a $K_i = 5 \pm 1 \mu\text{M}$ as compared to $K_i = 15 \pm 2 \mu\text{M}$ for **19b**.

Furthermore, the effect of the C-terminal substitution was explored on these compounds by adding a C-terminal benzamide. A slight improvement in K_i values was observed for compounds **20a** and **20b** ($K_i = 3.9 \pm 1$ and $6.8 \pm 1 \mu\text{M}$, respectively) (Figure 5A).

Finally, this tyrosyl-histidyl-benzylamide moiety was used to obtain the corresponding compounds derived from the *m*-sulfonamido- β -phenylalaninethiol **3** (Figure 5B). These molecules (**21a**, **21b**, **21c**, and **21d**) correspond to the four possible diastereomers. No significant improvement were obtained for compounds **21a** and **21b** possessing *S* absolute configuration at the level of the C3 carbon as compared to compounds **20a** and **20b** with K_i values equal to 3.0 ± 0.9 and $9.6 \pm 0.9 \mu\text{M}$, respectively (Figure 5). Interestingly, the compounds **21c** and **21d**, corresponding to the *R* absolute configuration at the level of the C3 carbon, did not demonstrate significant differences in terms of inhibitory potency ($K_{i21c} = 6.0 \pm 0.9 \mu\text{M}$ and $K_{i21d} = 4.0 \pm 0.9 \mu\text{M}$) as compared to those with the *S* configuration.

Finally, the evaluation of the kinetics of action of one of these inhibitors was undertaken. The cleavage rate of the fluorescent substrate [Pya⁸⁸]S39-88 by TeNt³⁹ was determined with concentrations of substrate ranging from 40 to 200 μM and with concentrations of compound **21c** ranging from 1 to 100 μM . The Lineweaver–Burk plot in Figure 6 represents the mean of three independent experiments performed in triplicate. This representation is particularly useful to determine a decrease of K_m and an unchanged V_{max} with increasing concentrations of inhibitors, which is the typical feature of a competitive inhibitor.

Discussion

The inhibitory potencies recently obtained with β -glutaminethiol **1** ($K_i = 250 \mu\text{M}$) and *m*-sulfonamido- β -phenylalaninethiol **3** ($K_i = 35 \mu\text{M}$)²² (Figure 2A) have shown that compounds capable of interacting with the S_1 subsite and the Zn metal atom are potent neurotoxin inhibitors. With the aim of improving the inhibitory




Figure 6. Lineweaver–Burk plot analysis of the inhibitory activity of compound **21c** for TeNt. The experiments were performed at 37 °C in 20 mM Hepes buffer (pH 7.4) containing 100 mM NaCl and 0.1 mM DTT. The enzymatic hydrolysis rates of the fluorescent substrate [Pya⁸⁸]S39-88 at different concentrations (40, 50, 66, 100, 200 μM) were determined by RP-HPLC quantitation of the appearance of the fluorescent cleavage product [Pya⁸⁸]S77-88 in the absence or presence of different concentrations (1, 10, 33, 100 μM) of inhibitor. Each point of the Lineweaver–Burk plot represents the mean of three independent experiments performed in triplicate.

potencies of these compounds, they were modified to incorporate moieties able to interact with the S' subsites of TeNt (Figure 2). This approach has already been used successfully in the rational design of inhibitors of other Zn peptidases, in particular aminopeptidases.²³

The improvement of the inhibitory potencies of the extended compounds **15–18** ($K_i = 80–100 \mu\text{M}$), as compared to their parent compound **1** ($K_i = 250 \mu\text{M}$) (Figure 2), confirmed the validity of this strategy. To optimize the interaction of these molecules with the S_1' and S_2' subsites of TeNt, the use of combinatorial chemistry techniques was chosen. Indeed combinatorial chemistry^{40–42} has recently emerged as a powerful method, complementary to structure-based ligand design,^{43,44} for the discovery and optimization of ligands for a variety of enzymes and receptors. Such methods reduce the need for repetitive syntheses of related compounds as well as laborious and expensive screening. Moreover they have been already successfully used in the design of inhibitors of zinc metallopeptidases such as angiotensin-converting enzyme,⁴⁵ matrix metalloproteinases,⁴⁶ and zinc endopeptidases 24.15³⁵ and 24.16.³⁶

Thus a library of 19 mixtures of 38 pseudotripeptides, derived from the sulfonamide analogue of β -glutaminethiol and containing natural amino acids, was synthesized and screened against TeNt (Figure 4). The best compound issuing from this library possessed a tyrosyl and a histidyl residue putatively interacting with the S_1' and S_2' subsites of TeNt, respectively. Nevertheless, very few differences, in terms of percentage of inhibition, were observed (Figure 4), indicating an apparent low specificity of the TeNt subsites. This contrasts with the importance of subsite specificity observed for other zinc endopeptidases using the same combinatorial approach.^{35,36} The best compound issuing from the libraries (Tyr-His) was purified, and the two diastereomers were separated (**19a** and **19b**). The best K_i value ($5 \pm 1 \mu\text{M}$) was obtained with the compound whose absolute configuration is *2R,3S* on the sulfonamide synthon (Figure 5A). A slight improvement was observed by adding a C-terminal benzylamide to these molecules especially on the *2S,3S* diastereomer resulting in K_i

values that decrease from 15 to 6.8 μM . This tyrosyl-histidyl-benzylamide moiety was introduced in pseudotriptides derived from the *m*-sulfonamido- β -phenylalaninethiol **3** whose K_i was 35 μM on TeNt²² (Figure 2). The four corresponding diastereomers, obtained by introducing the different synthons of absolute configuration *S* or *R* on the C2 and C3 carbons, were synthesized and unambiguously assigned. Still no tremendous differences of activity were obtained with these compounds, their K_i values ranging from 3 to 9.6 μM .

Such a lack of specificity in the stereochemistry of residues at the level of S_1 subsite is unexpected for zinc peptidases.^{6,47,48} To check if our molecules were interacting with the zinc atom of TeNt via the thiol group, we performed the synthesis of an analogue of compound **21** with a hydrogen replacing the free SH. This was achieved by coupling the corresponding acid synthon of *m*-sulfonamido- β -phenylalaninethiol **13b** to tyrosyl-histidyl-benzylamide (Scheme 2). This compound was devoid of any inhibitory activity even at 1 mM (data not shown). This clearly demonstrated that the thiol group was crucial for the activity of our compounds, probably via zinc chelation. Furthermore, the kinetics of action of compound **21c** was evaluated. The Lineweaver–Burk plot analysis of the experiments indicated the typical pattern observed for inhibitors competing with the substrate at the level of the active site.

The difficulty in improving the affinity of inhibitors for TeNt could be related to the mechanism of TeNt enzymatic activity. Indeed, it has recently been demonstrated that the shortest fragment of synaptobrevin behaving as a substrate contains 50 residues (sequence 39–88).^{18,39,49} Thus, short synaptobrevin sequences surrounding the cleavage site (G⁷³ASQFETSA⁸¹) are neither substrates nor inhibitors of TeNt proteolytic activity.^{11,19} This appears to be due to the lack of N- and C-terminal acidic and basic sequences of synaptobrevin distal from the cleavage site.^{15,17} The binding of these sequences to TeNt activates the proteolytic activity of TeNt probably by a transconformation,¹⁶ as occurs in allosteric-type enzymatic mechanisms. Our inhibitors, designed to interact with the active site via zinc chelation and catalytic subsite recognition, are competing with the synaptobrevin substrate once it is already bound to TeNt via its N- and C-terminal domains. This is an unfavorable situation which could explain the micromolar inhibitory potencies observed. Nevertheless, the inhibitory potencies of our inhibitors were not modified by addition of peptidic fragments corresponding to these allosteric effectors¹⁶ in the incubation medium (data not shown). This is not surprising because it has been recently shown that a small synaptobrevin sequence encompassing the cleavage site (G⁷³ASQFETSA⁸¹) is not cleaved by TeNt even in the presence of 1 mM S_1 (27–55) and S_2 (82–93) (unpublished results), while the sequence 56–81 is cleaved.¹⁶ Thus, even residues localized in the 56–72 sequence of synaptobrevin are involved in the enzyme–substrate recognition, and S_1 and S_2 sequences of synaptobrevin are required but not sufficient for the hydrolysis to occur.

In conclusion, this study raises important points in the understanding of tetanus neurotoxin proteolytic activity. Moreover, the combinatorial approach reported here led to the design of new pseudotriptides, with

K_i values against TeNt endopeptidase activity in the 3–4 μM range. Such an inhibitory potency has never been reached until now for any clostridial neurotoxin. Ex vivo and in vivo studies of these compounds are now in progress.

Experimental Section

Inhibitory Potency. Enzymatic studies were performed using synaptobrevin [Pya⁸⁸]S39-88 as a substrate according to the protocol described by Solheihac et al.³⁹ with slight modifications.²²

Chemistry. Solvents, reagents, and protected amino acids for peptide synthesis were obtained from Perkin-Elmer (Les Ulis, France). High-performance liquid chromatography (HPLC) grade solvents and solvents were from SDS (Peypin, France). Melting points of the crystallized compounds were measured on an electrothermal apparatus and are reported uncorrected. Flash chromatography was carried out with Merck silica gel 60 (230–400 Mesh). TLC was performed on precoated silica gel plates (60 F₂₅₄, 0.2 mm thick; Merck). Plates were developed with UV light, iodine vapor, or ninhydrin. The purity of the final compounds was also checked by HPLC using a reverse-phase column (Nucleosil, C₁₈, 150 \times 4.6 mm, 5 μm , 100 Å, flow rate 1 mL/min) with eluents A (H₂O, TFA 0.1% (v/v)) and B (CH₃CN/H₂O (7:3), TFA 0.09% (v/v)), on an Applied Biosystem 151A HPLC apparatus. The eluted peaks were monitored at 214 nm.

The structure of all the compounds was confirmed by ¹H NMR spectroscopy (Brüker AC 270 MHz or Brüker AM 400 MHz) in DMSO-*d*₆ or CDCl₃ or D₂O solutions (5 \times 10^{−3} M) using HMDS as internal reference. The signals are described as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and br (broad). Satisfactory elemental analyses, performed at the university of Paris VI, were obtained (C, H, N) for all compounds. Optical rotations were measured on a Perkin-Elmer 241 polarimeter (1.0 dm cell) for MeOH solutions at 20 °C. $\{\alpha\}_D$ values are given in units of 10^{−1} deg cm² g^{−1}. Mass spectral analyses were performed by Quad Service (Poissy, France) using the electrospray ionization (ESI) technique.

Abbreviations: BOP, (benzotriazolyl-1-yl)oxytris(dimethylamino)phosphonium hexafluorophosphate; HATU, *O*-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; Pya, pyrenylalanine; BBTO, bis(tributyltin) oxide; TeNt, tetanus neurotoxin; BoNt/A, botulinum neurotoxin type A.

Solid-Phase Synthesis of the Library. Solid-phase syntheses were performed with an automated 357 Advanced Chemtech multiple peptide synthesizer using a previously described procedure.^{35,36} The synthon B was incorporated as a building block during the solid-phase peptide synthesis.

Fully protected peptides were cleaved from 2-chlorotriptyl resin with 5 mL of a mixture of TFE and CH₂Cl₂ (2/8) during 4 h.³⁸ Solutions of protected peptides were concentrated in vacuo. Protective groups were removed by 10 mL of TFA containing 0.5 mL of H₂O and 0.25 mL of triisopropylsilane.³² Solutions of deprotected peptides were concentrated in vacuo and freeze-dried, and a final cleavage of the thiol protecting group (4-methoxybenzyl) and the benzyl carbamate was achieved by using 5 mL of anhydrous HF in the presence of *m*-cresol (100 μL) during 1 h at 0 °C.³³ After removal of HF in vacuo, the tripeptides were solubilized with 1.5 mL of TFA, precipitated with ether/hexane (1/1) (25 mL), and freeze-dried after addition of water. The correct stoichiometric content of peptide mixture in each expected amino acid was verified by quantitative amino acid analyses.

Construction of the Peptide Library by Combinatorial Chemistry. The protocol employed to synthesize the various mixtures of thiol-containing peptides of formula (synthon B)-AA'_{1x}-AA'_{2x}, where AA'_{1x} and AA'_{2x} represent 19 different natural amino acids (Cys was omitted) was previously described.^{35,36}

Synthesis of (2*SR*,3*S*)-3-(Boc-amino)-2-[(4-methoxybenzyl)sulfanyl]-6-oxo(tritylamino)hexanoic Acid (Synthon A). Methyl (3*S*)-3-(Boc-amino)-6-oxo(tritylamino)-

hexanoate (5a). Compound **5a** was prepared by using a previously described procedure.²³ To a solution of compound Boc-Gln(Trt)-OH (**4a**) (4.48 g, 10 mmol) and *N*-methylmorpholine (1.2 mL, 11 mmol) in THF (50 mL) at -15°C under nitrogen was added, over a 5-min period, isobutyl chloroformate (1.44 mL, 11 mmol). After the mixture stirred for 20 min at -20°C , the *N*-methylmorpholine hydrochloride was removed by filtration and the filter cake was washed with a small portion of cold THF. The filtrate was treated with a cold (-78°C) ethereal solution of diazomethane (prepared from 4.3 g (20 mmol) of diazald and distilled). The reaction mixture was allowed to reach room temperature and stirred for 1 h. After THF was removed in vacuo, the crude product was solubilized in ethyl acetate, washed with H_2O , NaHCO_3 (10%), and brine, and dried with Na_2SO_4 . The solvent was then evaporated to afford the corresponding diazo ketone (4.45 g, 8.7 mmol). To a solution of this diazo ketone in anhydrous MeOH (20 mL) was added silver benzoate (119 mg, 0.52 mmol) in triethylamine (12 mL). The solution darkened, and rapid gas evolution was noted. After the mixture was stirred for 90 min, Celite and decolorizing carbon was added. After stirring, the mixture was filtered through Celite and the filtrate concentrated. The residue was dissolved in EtOAc and washed with water, 1 N NaHCO_3 , 1 N KHSO_4 , and brine. After drying (Na_2SO_4), the solvent was removed at reduced pressure and the crude product chromatographed (cyclohexane/ CH_2Cl_2 /AcOEt, 5/3/2) to give 4.35 g of compound **5a** as a colorless solid (84% yield): R_f (AcOEt: CH_2Cl_2 , 1:3) = 0.58; ^1H NMR (DMSO- d_6) δ 1.32 (9H, s, tBu), 1.25–1.37 (1H, m, $\text{CH}-\text{CH}_2-\text{CH}_2$), 1.40–1.53 (1H, m, $\text{CH}-\text{CH}_2-\text{CH}_2$), 2.20 (2H, t, $\text{CH}-\text{CH}_2-\text{CH}_2$), 2.30 (2H, d, CH_2COOMe), 3.50 (3H, s, COOMe), 3.63–3.77 (1H, m, $\text{CH}-\text{CH}_2-\text{CH}_2$), 6.67 (1H, d, $\text{NH}-\text{Boc}$), 7.08–7.22 (15H, m, Trt), 8.50 (1H, s, $\text{NH}-\text{Trt}$). Anal. ($\text{C}_{31}\text{H}_{36}\text{N}_2\text{O}_5$) C, H, N.

Methyl (2*S*,3*S*)-3-(Boc-amino)-2-[(4-methoxybenzyl)sulfanyl]-6-oxo(tritylamino)hexanoate (6a). This compound was prepared according to the procedure described in Bischoff et al.²⁴ To a solution of compound **5a** (1.032 g, 2 mmol) in tetrahydrofuran (20 mL) at -78°C under nitrogen was added dropwise a solution of lithium diisopropylamide (1.6 M) (4.8 mL, 7.6 mmol) in THF/heptane/ethylbenzene. After 30 min of reaction time, a solution of 4-methoxy-2,4-dinitrophenyl disulfide (700 mg, 2.2 mmol) in 8 mL of THF was added, and the solution stirred for 2 h. The reaction was stopped by adding KHSO_4 (1 N) and extracted with ethyl acetate. The organic layer was washed by KHSO_4 (1 N) and brine, dried (Na_2SO_4), and then evaporated at reduced pressure. The crude product was chromatographed (AcOEt/ CH_2Cl_2 /cyclohexane, 2/3/5) to obtain 574 mg of compound **6a** (43% yield): R_f (AcOEt: CH_2Cl_2 :cyclohexane, 20:30:50) = 0.27; ^1H NMR (DMSO- d_6) δ 1.32 (9H, s, tBu), 1.28–1.37 (1H, m, $\text{CH}-\text{CH}_2-\text{CH}_2$), 1.86–1.95 (1H, m, $\text{CH}-\text{CH}_2-\text{CH}_2$), 2.10–2.24 (2H, m, $\text{CH}-\text{CH}_2-\text{CH}_2$), 3.22 (1H, m, $\text{CH}-\text{S}$), 3.55 (3H, s, COOMe), 3.67 (5H, 2s, $\text{S}-\text{CH}_2-\text{C}_6\text{H}_4-\text{OMe}$), 3.70–3.78 (1H, m, $\text{CH}-\text{CH}_2-\text{CH}_2$), 6.72 (1H, d, $\text{NH}-\text{Boc}$), 6.79 (2H, d, H_3, H_5 PhOMe), 7.12 (2H, d, H_2, H_6 PhOMe), 7.10–7.23 (15H, m, Trt), 8.50 (1H, s, $\text{NH}-\text{Trt}$); MS (EI) 153, 243, 559, 669. Anal. ($\text{C}_{39}\text{H}_{44}\text{N}_2\text{O}_6\text{S}$) C, H, N.

(2*SR*,3*S*)-3-(Boc-amino)-2-[(4-methoxybenzyl)sulfanyl]-6-oxo(tritylamino)hexanoic Acid (Synthon A). Compound **6a** (334 mg, 0.5 mmol) was treated by 1 M NaOH in MeOH/ H_2O (1/1). After classical workup, the solvent was removed in vacuo to afford 317 mg of synthon A (95% yield): mp = 118°C ; R_f (MeOH: CH_2Cl_2 , 10:90) = 0.4; ^1H NMR (DMSO- d_6) δ 1.30 (1.39) (9H, s, tBu), 1.55–1.66 (1H, m, $\beta\text{CH}_2(\text{Gln})$), 1.80–1.93 (1H, m, $\beta\text{CH}_2(\text{Gln})$), 2.13–2.26 (2H, m, $\gamma\text{CH}_2(\text{Gln})$), 3.12 (3.18) (1H, d, $\text{CH}-\text{S}$), 3.68 (5H, s, $\text{CH}_2-\text{C}_6\text{H}_5-\text{OCH}_3$), 3.70–3.80 (1H, m, $\alpha\text{CH}(\text{Gln})$), 3.62(3.70) (1H, d, BocNH), 6.80 (2H, d, H_3, H_5 PhOMe), 7.12 (2H, d, H_2, H_6 PhOMe), 7.10–7.25 (15H, m, Trt), 8.48 (8.52) (1H, s, NHTrt); $\{\alpha\}_D = -9.4$ (MeOH). Anal. ($\text{C}_{38}\text{H}_{42}\text{N}_2\text{O}_6\text{S}$) C, H, N.

***N*-[(2*SR*,3*S*)-3-Amino-5-carbamoyl-2-sulfanylpentanoyl]-L-phenylalanine (15).** Synthon A (100 mg) was coupled with H-Phe-OtBu using BOP as coupling agent as previously described.⁵⁰ After classical workup and deprotection by TFA³² and anhydrous hydrogen fluoride,³³ 54 mg of crude product

15 was obtained by purification on a semipreparative HPLC with a C18 Vydac column (5 μM , 100 \AA , 10×250 mm) (38% yield): retention time = 12.1 min (Nucleosil, C8, 150×4.6 mm, 5 μm , 100 \AA , gradient 0–40% B in 15 min, flow rate = 1 mL/min, $\lambda = 214$ nm); purity > 99%; ^1H NMR (DMSO- d_6) δ 1.37 (1H, m, β (Gln)), 1.50 (1H, m, β (Gln)), 2.08 (2H, t, γ (Gln)), 2.82 (1H, dd, β (Phe)), 3.06 (1H, dd, β (Phe)), 3.15 (1H, m, CHNH_3^+), 3.51 (1H, d, CHSH), 4.40 (1H, m, α (Phe)), 7.00 (1H, s, CONH_2), 7.13–7.22 (5H, m, Ph), 7.40 (1H, s, CONH_2), 8.77 (1H, d, $\text{NH}(\text{Phe})$); MS (ESI) ($\text{M} + \text{H}^+$) $m/z = 340.1$. Anal. ($\text{C}_{15}\text{H}_{21}\text{N}_3\text{O}_4\text{S}$).

***N*-[(2*SR*,3*S*)-3-Amino-5-carbamoyl-2-sulfanylpentanoyl]-L-phenylalanyl-L-glutamic Acid (16).** Synthon A (150 mg) was coupled with H-Phe-Glu(tBu)-2-chlorotrityl resin using BOP as previously described.⁵⁰ After deprotection by trifluoroacetic acid³² and anhydrous hydrogen fluoride,³³ the crude product **16** was obtained and purified by semipreparative HPLC on a Vydac C18 column (5 μM , 100 \AA , 10×250 mm) (29% yield): retention time = 10.8 min (Nucleosil, C8, 150×4.6 mm, 5 μm , 100 \AA , gradient 0–40% B in 15 min, flow rate = 1 mL/min, $\lambda = 214$ nm); purity > 99%; ^1H NMR (DMSO- d_6) δ 1.29 (1H, m, β (Gln)), 1.43 (1H, m, β (Gln)), 1.78 (1H, m, β (Glu)), 1.84 (1H, m, β (Glu)), 2.04 (2H, t, γ (Gln)), 2.26 (2H, t, γ (Glu)), 2.69 (1H, dd, β (Phe)), 3.03 (1H, dd, β (Phe)), 3.09 (1H, m, CHNH_3^+), 3.55 (1H, d, CHSH), 4.20 (1H, m, α (Glu)), 4.60 (1H, m, α (Phe)), 7.00 (1H, s, CONH_2), 7.12–7.27 (5H, m, Ph), 7.40 (1H, s, CONH_2), 7.93 (3H, br s, NH_3^+), 8.40 (1H, d, $\text{NH}(\text{Glu})$), 8.67 (1H, d, $\text{NH}(\text{Phe})$); MS (ESI) ($\text{M} + \text{H}^+$) $m/z = 469.2$. Anal. ($\text{C}_{20}\text{H}_{28}\text{N}_4\text{O}_7\text{S}$).

***N*-[(2*SR*,3*S*)-3-Amino-5-carbamoyl-2-sulfanylpentanoyl]-L-phenylalanyl-L-glutamyl-L-threonine (17).** Synthon A (150 mg) was coupled with H-Phe-Glu(tBu)-Thr(tBu)-2-chlorotrityl resin to give, by the procedure described for compound **16**, crude product **17** which was purified by semipreparative HPLC on C18 Vydac column (5 μM , 100 \AA , 10×250 mm) (27% yield): retention time = 11.6 min (Nucleosil, C8, 150×4.6 mm, 5 μm , 100 \AA , gradient 0–40% B in 15 min, flow rate = 1 mL/min, $\lambda = 214$ nm); purity > 99%; ^1H NMR (DMSO- d_6) δ 1.02 (3H, d, γ (Thr)), 1.28 (1H, m, β (Gln)), 1.43 (1H, m, β (Gln)), 1.76 (1H, m, β (Glu)), 1.90 (1H, m, β (Glu)), 2.07 (2H, t, γ (Gln)), 2.28 (2H, t, γ (Glu)), 2.68 (1H, dd, β (Phe)), 3.03 (1H, dd, β (Phe)), 3.08 (1H, m, CHNH_3^+), 3.54 (1H, d, CHSH), 4.11 (1H, m, β (Thr)), 4.16 (1H, m, α (Thr)), 4.40 (1H, m, α (Glu)), 4.60 (1H, m, α (Phe)), 4.93 (1H, br s, OH), 7.00 (1H, s, CONH_2), 7.10–7.20 (5H, m, Ph), 7.42 (1H, s, CONH_2), 7.83 (1H, d, $\text{NH}(\text{Thr})$), 7.92 (3H, br s, NH_3^+), 8.30 (1H, d, $\text{NH}(\text{Glu})$), 8.67 (1H, d, $\text{NH}(\text{Phe})$), 12.35 (2H, br s, COOH); MS (ESI) ($\text{M} + \text{H}^+$) $m/z = 570.3$. Anal. ($\text{C}_{24}\text{H}_{35}\text{N}_5\text{O}_9\text{S}$).

***N*-[(2*SR*,3*S*)-3-Amino-5-carbamoyl-2-sulfanylpentanoyl]-L-phenylalanyl-L-glutamyl-L-threonyl-L-serine (18).** Synthon A (150 mg) was coupled with H-Phe-Glu(tBu)-Thr(tBu)-Ser(tBu)-2-chlorotrityl resin as described for compound **16**. Crude product **18** was purified by semipreparative HPLC on C18 Vydac column (5 μM , 100 \AA , 10×250 mm) (32% yield): retention time = 13.9 min (Nucleosil, C8, 150×4.6 mm, 5 μm , 100 \AA , gradient 0–40% B in 15 min, flow rate = 1 mL/min, $\lambda = 214$ nm); purity > 99%; ^1H NMR (DMSO- d_6) δ 1.04 (3H, d, γ (Thr)), 1.25 (1H, m, β (Gln)), 1.42 (1H, m, β (Gln)), 1.73 (1H, m, β (Glu)), 1.89 (1H, m, β (Glu)), 2.03 (2H, t, γ (Gln)), 2.24 (2H, t, γ (Glu)), 2.65 (1H, dd, β (Phe)), 3.03 (1H, dd, β (Phe)), 3.04 (1H, m, CHNH_3^+), 3.52 (1H, d, CHSH), 3.57 (1H, dd, β (Ser)), 3.68 (1H, dd, β (Ser)), 3.94 (1H, m, β (Thr)), 4.23 (1H, m, α (Ser)), 4.27 (1H, m, α (Thr)), 4.33 (1H, m, α (Glu)), 4.60 (1H, m, α (Phe)), 4.96 (2H, br s, OH(Ser) and OH(Thr)), 7.03 (1H, s, CONH_2), 7.10–7.24 (5H, m, Ph), 7.42 (1H, s, CONH_2), 7.78 (1H, d, $\text{NH}(\text{Thr})$), 7.92 (2H, br s, NH_2), 7.93 (1H, d, $\text{NH}(\text{Ser})$), 8.36 (1H, d, $\text{NH}(\text{Glu})$), 8.69 (1H, d, $\text{NH}(\text{Phe})$), 12.35 (2H, br s, COOH); MS (ESI) ($\text{M} + \text{H}^+$) $m/z = 657.4$. Anal. ($\text{C}_{27}\text{H}_{40}\text{N}_6\text{O}_{11}\text{S}$).

Synthesis of (2*SR*,3*S*)-4-(*tert*-Butylsulfamoyl)-2-(Cbz-amino)butanoic Acid (Synthon B). Methyl (3*S*)-5-(*tert*-Butylsulfamoyl)-3-(Cbz-amino)pentanoate (**5b**). Compound **5b** was prepared from **4b** (20 g, 53.7 mmol) (prepared as previously described²³) by the procedure described for **5a**.

Compound **5b** (20.1 g) was obtained as a colorless solid after flash chromatography (cyclohexane/CH₂Cl₂/AcOEt, 0.5/3/2) (95% yield): mp = 88 °C; *R*_f = 0.48 (AcOEt/CH₂Cl₂/cyclohexane, 1/1/1); ¹H NMR (CDCl₃) δ 1.29 (9H, s, tBu), 1.99 (2H, m, CH₂CH₂SO₂NH), 2.54 (2H, d, CH₂COOMe), 3.05 (2H, t, CH₂SO₂NH), 3.61 (3H, s, COOMe), 4.02 (1H, m, CHCH₂COOMe), 5.03 (2H, s, CH₂Ph), 4.14 (1H, s, NHtBu), 5.37 (1H, d, BzIOCONH), 7.28 (5H, m, Ph). Anal. (C₁₈H₂₈N₂O₆S) C, H, N.

Methyl (2*S*,3*S*)-5-(*tert*-Butylsulfamoyl)-3-(Cbz-amino)-2-[(4-methoxybenzyl)sulfanyl]pentanoate (6b). Compound **6b** was prepared from **5b** (1.5 g, 3.75 mmol) by using the procedure as described for **6a**. The crude residue obtained was chromatographed (AcOEt/CH₂Cl₂/cyclohexane, 2/3/5) to yield 1.1 g of compound **6b** (54% yield) (>95% ee according to HPLC monitoring): *R*_f (EtOAc/CH₂Cl₂/cyclohexane, 1/1/1) = 0.57; *R*_f (EtOAc/CH₂Cl₂/cyclohexane, 15/25/60) = 0.15; ¹H NMR (CDCl₃) δ 1.25 (9H, s, tBu), 1.86 to 2.30 (2H, m, CH-CH₂-CH₂), 2.96 (2H, t, CH-CH₂-CH₂), 3.29 (1H, d, CH-S), 3.64 (3H, s, COOMe), 3.72 (5H, s, S-CH₂-C₆H₄-OMe), 4.02 (1H, m, CH-CH₂-CH₂), 4.87 (1H, s, SO₂-NH), 4.95 (1H, d(AB), CH₂C₆H₅), 5.05 (1H, d(AB), CH₂C₆H₅), 5.50 (1H, d, NH-Z), 6.75 (2H, d, H₃,H₅ PhOMe), 7.14 (2H, d, H₂,H₆ PhOMe), 7.37 (5H, m, Ph); MS (ES) (M + H)⁺ *m/z* = 539.3, (M + Na)⁺ 561.3. Anal. (C₂₆H₃₆N₂O₇S₂) C, H, N.

(2*S*,3*S*)-5-(*tert*-Butylsulfamoyl)-3-(Cbz-amino)-2-[(4-methoxybenzyl)sulfanyl]pentanoic Acid (Synthon B). The compound **6b** (0.55 g, 1 mmol) was hydrolyzed by 3 M NaOH in MeOH overnight at room temperature to afford 0.48 g of synthon B (91% yield): mp = 70 °C; *R*_f (EtOAc/AcOH/CH₂Cl₂, 30/2/70) = 0.24 and 0.32; retention time = 10.4 and 11.8 min (Chirose bond, C1, 250 × 4.6 mm, 5 μm, isocratic conditions: 30% of B'' with A''-phosphate buffer (0.05 M, pH = 6); B'':CH₃CN, flow rate = 1 mL/min); ¹H NMR (CDCl₃) δ 1.21 (9H, s, tBu), 1.79 to 1.93 (1H, m, CH-CH₂-CH₂), 1.96 to 2.10 (1H, m, CH-CH₂-CH₂), 2.97 (2H, t, CH-CH₂-CH₂), 3.70 (3H, s, OMe), 3.76 (2H, s, CH₂-CH₄-OMe), 4.04 (1H, m, CH-CH₂-CH₂), 5.01 (2H, s, CH₂-C₆H₅), 5.60 (1H, d, NH-Z), 6.72 and 6.77 (2H, d, H₃,H₅ PhOMe), 7.12 and 7.17 (2H, d, H₂,H₆ PhOMe), 7.25 (5H, br s, Ph); MS (ESI) (M + H)⁺ *m/z* = 539.3, 561.3 (Na⁺) Anal. (C₂₅H₃₄N₂O₇S₂) C, H, N.

N-[(2*S*,3*S*)-3-Amino-5-sulfamoyl-2-sulfanyl]pentanoyl-L-tyrosyl-L-histidine (19a and 19b). To 135 mg (250 μmol) of synthon B, 122 mg (320 μmol) of HATU, and 150 μmol of H-Tyr(tBu)-His(Trt)-2-chlorotriyl resin in 5 mL of NMP (*N*-methylpyrrolidone) was added at room temperature 200 μL of DIEA. After 6 h of stirring and negative Kaiser test, the peptidyl resin was successively washed with NMP and CH₂Cl₂. After deprotection by trifluoroacetic acid³² and anhydrous hydrogen fluoride,³³ the crude products **19a** and **19b** were purified and separated by semipreparative HPLC on a C18 Vydac column (5 μm, 100 Å, 10 × 250 mm) (22% and 17% yields, respectively, λ = 214 nm): purity > 99%; retention time = 10.6 min (**19a**, **2*R*,3*S***) and 11.5 min (**19b**, **2*S*,3*S***) (Nucleosil, C18, 150 × 4.6 mm, 5 μm, 100 Å, gradient 0–40% B in 15 min, flow rate = 1 mL/min); ¹H NMR (D₂O) δ 2.12 (2H, m, CH-CH₂-CH₂), 2.96 (2H, dd, β(Tyr)), 3.08 (1H, dd, β(His)), 3.18 (1H, dd, β(His)), 3.33 (2H, t, CH-CH₂-CH₂), 3.70 (1H, d, CH-SH), 3.72 (1H, m, CH-CH₂-CH₂), 4.22 (1H, d, CH₂-C₆H₅), 4.37 (1H, d, CH₂-C₆H₅), 4.55 (1H, t, α(Tyr)), 4.60 (1H, t, α(His)), 6.82 (2H, d, H₃-H₅(Tyr)), 7.13 (2H, d, H₂-H₆(Tyr)), 7.14 (1H, s, H₄(His)), 7.19 (2H, d, C₆H₅), 7.37 (3H, m, C₆H₅), 8.51 (1H, s, H₂(His)); MS (ESI) (M + H)⁺ *m/z* = 529.1, (M + 2H)⁺ 265.2. Anal. (C₂₀H₂₈N₆O₇S₂).

N-[(2*S*,3*S*)-3-Amino-5-sulfamoyl-2-sulfanyl]pentanoyl-L-tyrosyl-N-benzyl-L-histidinamide (20a and 20b). To 300 mg (0.57 mmol) of synthon B, 260 mg (0.68 mmol) of HATU, and 470 mg (0.68 mmol) of H-Tyr(tBu)-His(Trt)-NHBz in CH₂Cl₂ (5 mL) was added 350 μL of DIEA. After stirring for 6 h at room temperature and classical workup, 460 mg of crude protected product treated by trifluoroacetic acid³² and anhydrous hydrogen fluoride³³ led to the mixture of **19a** and **19b**. The two diastereomers were separated by semipreparative HPLC on a C18 Vydac column (5 μm, 100 Å, 10 × 250 mm) to yield 84 mg of **20a** (18% yield) and 67 mg of **20b** (14% yield):

retention time = 9.5 min (**20a**, **2*R*,3*S***) and 9.9 min (**20b**, **2*S*,3*S***) (Nucleosil, C18, 150 × 4.6 mm, 5 μm, 100 Å, gradient 20–60% B in 15 min, flow rate = 1 mL/min, λ = 214 nm); purity > 99%; ¹H NMR (D₂O) δ 1.93–2.13 (2H, m, CH₂-CH₂-SO₂NH), 2.87 and 3.08 (2H, dd, β(Tyr)), 2.98 (1H, dd, β(His)), 3.17 and 3.18 (1H, dd, β(His)), 3.29 and 3.31 (2H, t, CH₂-CH₂-SO₂NH), 3.66 and 3.68 (1H, d, CH-SH), 3.70 and 3.72 (1H, m, CH-CH₂-CH₂), 4.58 (1H, t, α(Tyr)), 4.63 (1H, t, α(His)), 6.78 and 6.82 (2H, d, H₃-H₅(Tyr)), 7.09 and 7.13 (2H, d, H₂-H₆(Tyr)), 7.14 and 7.23 (1H, s, H₄(His)), 8.48 and 8.51 (1H, s, H₂(His)); MS (ESI) (M + H)⁺ *m/z* = 618.1. Anal. (C₂₇H₃₅N₇O₆S₂).

Synthesis of (2*S*,3*S*)-3-(Boc-amino)-3-[3-(*tert*-butylsulfamoyl)phenyl]-2-[(4-methoxybenzyl)sulfanyl]propanoic Acid (Synthon C). 3-(*tert*-Butylsulfamoyl)benzoic Acid (**8**). To a solution of 75 g (340 mmol) of 3-(chlorosulfonyl)benzoic acid (**7**) (from Aldrich) in 1.5 L of CH₂Cl₂ was added at 0 °C 125 mL (1.19 mol, 0.8 M) of tBuNH₂. After 2 h stirring at room temperature, the final acid was extracted with NaOH (1 M) (three times) and the aqueous layer acidified with HCl (6 N). A white solid precipitated and was filtered. The filter cake was dried over P₂O₅ to obtain 68.36 g of **8** which was used without further purification (78% yield): *R*_f (AcOH/toluene, 3/7) = 0.45; ¹H NMR (DMSO-*d*₆) δ 1.05 (9H, s, tBu), 7.65 (1H, s, SO₂NH), 7.65 (1H, t, Ar), 8.00 (1H, d, Ar), 8.08 (1H, d, Ar), 8.33 (1H, s, Ar). Anal. (C₁₁H₁₅NO₄S) C, H, N.

N-*tert*-Butyl-3-(hydroxymethyl)benzenesulfonamide (9). A 12.94 g (50.3 mmol) portion of 3-(*tert*-butylsulfamoyl)benzoic acid was treated with 3 molar equiv of LiAlH₄²⁵ in THF to afford 10.9 g of **9** (90% yield): *R*_f (AcOOH/toluene, 3/7) = 0.24; ¹H NMR (DMSO-*d*₆) δ 1.04 (9H, s, tBu), 4.52 (2H, d, CH₂OH), 5.36 (1H, t, CH₂OH), 7.45 (1H, s, SO₂NH), 7.46 (1H, d, Ar), 7.46 (1H, d, Ar), 7.64 (1H, dd, Ar), 7.77 (1H, s, Ar). Anal. (C₁₁H₁₇NO₃S) C, H, N.

N-*tert*-Butyl-3-(oxomethyl)benzenesulfonamide (10). Compound **10** was synthesized by applying the Swern procedure²⁶ with slight modification. Briefly, to a solution of 4.7 mL (53.7 mmol) of oxalyl chloride (freshly distilled) in 100 mL of CH₂Cl₂ was added dropwise, at –60 °C, under N₂, a solution of 9.5 mL (134 mmol) of DMSO in 20 mL of CH₂Cl₂. The reaction was stirred for 5 min, and the alcohol **9** in 4 mL of DMSO and 30 mL of CH₂Cl₂ was added within 5 min. Stirring was continued for an additional 30 min at the same temperature; 31.2 mL (224 mmol) of triethylamine was then added, and the reaction mixture was stirred for 5 min at –65 °C and then allowed to warm to room temperature. After 1 h of stirring, water was added and the aqueous layer was reextracted with additional CH₂Cl₂. The organic layers were combined, washed with KHSO₄ (1 N), NaHCO₃ (10%), and brine, and dried over Na₂SO₄ to give after concentration in vacuo 10.45 g of compound **10** (96% yield): *R*_f (AcOEt/cyclohexane, 1/2) = 0.32; ¹H NMR (DMSO) δ 1.05 (9H, s, tBu), 7.70 (1H, s, SO₂NH), 7.78 (1H, t, Ar), 8.10 (2H, d, Ar), 8.29 (1H, s, Ar), 10.05 (1H, s, CHO). Anal. (C₁₁H₁₅NO₃S) C, H, N.

Ethyl 3-[3-(*tert*-Butylsulfamoyl)phenyl]propenoate (11). A 20.4 mL (102 mmol) portion of triethyl phosphonoacetate was added dropwise to a suspension of sodium hydride (3 g, 104 mmol) in dry DME (200 mL) using a previously described protocol.²⁷ After the mixture stirred for 30 min at 45 °C, 16.8 g (69.6 mmol) of aldehyde **10** was added rapidly, and the mixture was stirred for 1 h at 50 °C. The reaction was poured into 250 mL of ice-water and extracted with ethyl acetate (2 × 250 mL). The ethyl acetate solution was washed with water and brine, dried over Na₂SO₄, filtered, and evaporated in vacuo; 20.56 g of compound **11** (85% yield) was isolated as a white solid after crystallization in ether/heptane (1/1): *R*_f (AcOEt/cyclohexane, 4/6) = 0.40; ¹H NMR (DMSO) δ 1.05 (9H, s, tBu), 1.20 (3H, t, CH₃-CH₂), 4.15 (2H, q, CH₃-CH₂), 6.65 (1H, *J* = 16 Hz, d, ϕ CH=CH), 7.50 (1H, s, SO₂NH), 7.58 (1H, t, Ar), 7.68 (1H, t, CH=CH-COOEt), 7.82 (1H, d, Ar), 7.91 (1H, d, Ar), 8.10 (1H, s, Ar). Anal. (C₁₅H₂₁NO₄S) C, H, N.

Ethyl 3(*R*)-3-[(*S*)-*N*-Benzyl-1-phenylethylamino]-3-[3-(*tert*-butylsulfamoyl)phenyl]propanoate (12a) and Ethyl 3(*S*)-3-[(*R*)-*N*-Benzyl-1-phenylethylamino]-3-[3-(*tert*-butylsulfamoyl)phenyl]propanoate (12b). Both diastereo-

isomers were synthesized by applying the procedure previously described.^{28,51} Briefly, to a solution of 4 g (18.9 mmol) of commercially available (*S*)-(-)-*N*-benzyl- α -methylbenzylamine (99%) (Aldrich) in 70 mL of dry THF was added, at 0 °C, 11.8 mL (18.9 mmol) of *n*BuLi (1.6 M in hexane) in 30 mL of THF. The reaction mixture was stirred for 15 min and cooled to -78 °C. A solution of 2.36 g (7.56 mmol) of **11** in 30 mL of THF was added dropwise to the reaction mixture which was stirred for 30 min; 30 mL of KHSO₄ (1 M) was then added. After evaporation of THF, the aqueous residue was extracted with EtOAc. The ethyl acetate layer was extracted with KHSO₄ (1 N), NaHCO₃ (10%), and brine, dried over Na₂SO₄, and evaporated in vacuo. The product was then purified by flash chromatography on a silica gel column using AcOEt/CH₂Cl₂/cyclohexane (1.5/1.5/7) as eluent to obtain 3.28 g of compound **12a** (87% yield) (>99% ee according to HPLC monitoring). (*R*)-(+)-*N*-Benzyl- α -methylbenzylamine was used to obtain **12b**: *R*_f (AcOEt/cyclohexane, 3/7) = 0.41; ¹H NMR (CDCl₃) δ 1.02 (3H, t, CH₂CH₃), 1.13 (9H, s, *t*Bu), 1.20 (3H, t, CH-CH₃), 2.57 (2H, m, CH₂-COOEt), 3.64 (2H, d, CH₂ ϕ), 3.84–3.95 (3H, m, CH₃-CH₂ and CH₃-CH), 4.47 (1H, dd, CH-CH₂-COOEt), 4.51 (1H, s, SO₂NH), 7.11–7.35 (10H, m, 2 ϕ), 7.39 (1H, dd, Ar), 7.51 (1H, d, Ar), 7.71 (1H, d, Ar), 7.90 (1H, s, Ar). **12a**: { α }_D = +5.6 (MeOH). Anal. (C₃₀H₃₈N₂O₄S) H, N; C: calcd, 68.94; found, 68.44.

Ethyl (3*R*)-3-(Boc-amino)-3-[3-(*tert*-butylsulfamoyl)-phenyl]propanoate (13a) and Ethyl (3*S*)-3-(Boc-amino)-3-[3-(*tert*-butylsulfamoyl)phenyl]propanoate (13b). A 3.28 g (6.28 mmol) portion of **12a** (respectively **12b**) and 4.8 g of Boc₂O were solubilized into 60 mL of AcOEt containing 4.4 g of Pd(OH)₂/C (20%). The reaction mixture was vigorously stirred under 20 bar of H₂ at 25 °C for 18 h. After filtration of the catalyst on Celite, the filtrate was evaporated in vacuo and purified on a silica gel column using AcOEt/cyclohexane (1/3) as eluent to obtain 2.28 g of compound **13a** (respectively **13b**) (85% yield): *R*_f (AcOEt/cyclohexane, 3/7) = 0.21; ¹H NMR (CDCl₃) δ 1.13 (3H, t, CH₂CH₃), 1.15 (9H, s, *t*Bu-NH-SO₂-), 1.35 (9H, s, Boc), 2.76 (2H, m, CH₂-COOEt), 3.99 (2H, q, CH₃-CH₂), 4.60 (1H, s, SO₂NH), 5.08 (1H, m, CH-CH₂-COOEt), 5.58 (1H, m, NH-Boc), 7.38 (1H, dd, Ar), 7.40 (1H, d, Ar), 7.72 (1H, d, Ar), 7.77 (1H, s, Ar). **13a**: { α }_D = +24.0 (MeOH). **13b**: { α }_D = -23.5 (MeOH). Anal. (C₂₀H₃₂N₂O₆S) H, N; C: calcd, 56.06; found, 56.65.

Ethyl (2*S*,3*S*)-3-(Boc-amino)-3-[3-(*tert*-butylsulfamoyl)-phenyl]-2-[(4-methoxybenzyl)sulfanyl]propanoate (14a) and Ethyl (2*R*,3*R*)-3-(Boc-amino)-3-[3-(*tert*-butylsulfamoyl)phenyl]-2-[(2,4-dimethoxybenzyl)sulfanyl]propanoate (14b). A 0.5 g (1.17 mmol) portion of **13a** was treated according to the procedure described for compound **5a**. The crude residue was purified on a silica gel column, using EtOAc/cyclohexane (1/3) as eluent, to yield 331 mg of compound **14a** (>85% ee according to HPLC monitoring) (49% yield): *R*_f (AcOEt/cyclohexane, 3/7) = 0.31; ¹H NMR (CDCl₃) δ 1.08 (3H, t, CH₂CH₃), 1.12 (9H, s, *t*Bu-NH-SO₂-), 1.36 (9H, s, Boc), 3.40 (1H, m, CH-COOEt), 3.75 (3H and 2H, s, OMe and ϕ -CH₂-S), 3.96 (2H, q, CH₃-CH₂), 4.51 (1H, s, SO₂NH), 5.00 (1H, m, BocNH-CH), 6.11 (1H, m, NH-Boc), 6.82 (2H, d, ϕ -OMe), 7.22 (2H, d, ϕ -OMe), 7.25 (1H, d, Ar), 7.30 (1H, t, Ar), 7.50 (1H, s, Ar), 7.68 (1H, d, Ar). Anal. (C₂₈H₄₀N₂O₇S₂) C, H, N.

According to a previously described protocol,³⁰ to a solution of 1,1,1,3,3,3-hexamethyldisilazane (6.4 mL, 3.5 molar equiv, 30.2 mmol) in THF (70 mL) at 0 °C was added a solution of *n*-butyllithium (2.5 M solution in hexane, 11 mL, 3.2 molar equiv). After stirring at this temperature for 10 min, the mixture was cooled to -78 °C and a solution of 3.7 g of **13b** (8.64 mmol) in 40 mL of THF was added dropwise. The stirred mixture was maintained at 30 °C for 2 h and then cooled to -78 °C and a solution of 2,4-dimethoxybenzylthio 4-methylphenyl sulfonate (3.7 g, 10.37 mmol) in 30 mL of THF was added. After stirring at this temperature for 1 h, the reaction mixture was poured into saturated aqueous ammonium chloride solution (50 mL), and the mixture obtained was extracted with diethyl ether (2 \times 300 mL). The combined extracts were washed with water and brine, dried over Na₂SO₄, and evapo-

rated in vacuo; 3.11 g of **14b** (59% yield) was obtained after flash chromatography: *R*_f (AcOEt/cyclohexane, 1/4) = 0.15; ¹H NMR (CDCl₃) δ 1.08 (3H, t, CH₂CH₃), 1.12 (9H, s, *t*Bu-NH-SO₂-), 1.35 (9H, s, Boc), 3.56 (1H, m, CH-COOEt), 3.79 (6H and 2H, s, OMe and ϕ CH₂S), 4.00 (2H, q, CH₃-CH₂), 4.51 (1H, s, SO₂NH), 5.06 (1H, m, Boc-NH-CH), 6.13 (1H, m, NH-Boc), 7.30–7.42 (3H, m, *F*(OMe)), 7.58–7.78 (4H, m, Ar).

(2*S*,3*S*)-3-(Boc-amino)-3-[3-(*tert*-butylsulfamoyl)-phenyl]-2-[(4-methoxybenzyl)sulfanyl]propanoic Acid and (2*S*,3*R*)-3-(Boc-amino)-3-[3-(*tert*-butylsulfamoyl)phenyl]-2-[(2,4-dimethoxybenzyl)sulfanyl]propanoic Acid. To a stirred solution of bis(tributyltin) oxide (BBTO) (5.3 mL, 10.33 mmol, 3 molar equiv) in 20 mL of CH₃CN was added 2 g of compound **14a** (3.44 mmol) solubilized in 6 mL of CH₃CN. The mixture was refluxed for 48 h, and 50 mL of CH₃CN was added. The organic phase was acidified with HCl (2 N), and the mixture was stirred for 30 min. After evaporation of CH₃CN and classical workup, the crude residue was purified on a silica gel column using AcOEt/cyclohexane/AcOH (45/55/2.5) as eluent; 1.3 g of synthon C (2*S*,3*S*) was thus obtained (70% yield): retention time = 11.8 min (2*S*,3*S*) (Chirose bond, C1, 250 \times 4.6 mm, 5 mm, isocratic at 30% of B'' with A'':phosphate buffer (0.05 M, pH = 6); B'':CH₃CN, flow rate = 1 mL/min).

A 0.33 g (0.57 mmol) portion of **14a** was hydrolyzed as described for synthon A to give 310 mg of a racemic mixture of synthon C (2*S*,3*S*) (98% yield): *R*_f (CH₂Cl₂/MeOH/AcOOH, 96/3/1) = 0.16; retention time = 11.8 min (2*S*,3*S*) and 10.7 min (2*R*,3*S*) (Chirose bond, C1, 250 \times 4.6 mm, 5 μ m, isocratic at 30% of B'' with A'':phosphate buffer (0.05 M, pH = 6); B'':CH₃CN, flow rate = 1 mL/min); ¹H NMR (CDCl₃) δ 1.11 and 1.12 (9H, s, *t*Bu-NH-SO₂-), 1.30 and 1.35 (9H, s, Boc), 3.40 and 3.45 (1H, m, CH-COOEt), 3.72 and 3.75 (3H and 2H, s, OMe and ϕ -CH₂-S), 3.65 (1H, s, SO₂NH), 5.05 and 5.32 (1H, m, BocNH-CH), 5.37 and 6.20 (1H, m, NH-Boc), 6.75 and 6.80 (2H, d, ϕ -OMe), 7.12 and 7.20 (2H, d, ϕ -OMe), 7.30 (1H, d, Ar), 7.40 (1H, t, Ar), 7.81 and 7.70 (1H, s, Ar), 7.68 and 7.75 (1H, d, Ar). 2*S*,3*R*: { α }_D = +29.8 (MeOH). 2*S*,3*S*: { α }_D = -29.2 (MeOH). Anal. (C₂₆H₃₆N₂O₇S₂) C, H, N.

A 0.35 g (0.57 mmol) portion of **14b** was saponified as described for synthon A to give 310 mg of 2*S*,3*R* (98% yield): *R*_f (CH₂Cl₂/MeOH/AcOOH, 96/3/1) = 0.16; retention time = 15.7 min (2*R*,3*R*) and 17.4 min (2*S*,3*R*) (Chirose bond, C1, 250 \times 4.6 mm, 5 mm, isocratic at 30% of B with A:phosphate buffer (0.05 M, pH = 6); B:CH₃CN, flow rate = 1 mL/min); ¹H NMR (DMSO-*d*₆) δ 0.98 and 1.00 (9H, s, *t*Bu-NH-SO₂-), 1.24 and 1.28 (9H, s, Boc), 3.53 and 3.63 (1H, d, CH-COOH), 3.61, 3.66, 3.68, 3.71, and 3.77 (6H and 2H, s, OMe and ϕ -CH₂-S), 4.81 (1H, m, BocNH-CH), 6.32 and 6.40 (1H, dd, ϕ -OMe), 6.40 and 6.47 (H, d, ϕ -OMe), 6.87 and 7.10 (1H, d, ϕ -OMe), 7.41–7.65 (5H, m, Ar and NH), 7.75 and 7.80 (1H, s, Ar). Anal. (C₂₇H₃₈N₂O₈S₂) C, H, N.

N-[(2*R*,3*S*)-3-Amino-3-(3-sulfamoylphenyl)-2-sulfanylpropanoyl]-L-tyrosyl-N-benzyl-L-histidinamide (21a and 21b). To 300 mg (0.57 mmol) of synthon C (2*S*,3*S*), 260 mg (0.68 mmol) of HATU, 470 mg (0.68 mmol) of H-Tyr(*t*Bu)-His(Trt)-NH-Bz, and 350 μ L of DIEA was added 5 mL of CH₂Cl₂. After stirring for 6 h at room temperature and classical workup, the residue was treated by trifluoroacetic acid³² to obtain 480 mg of crude product which was purified by semipreparative HPLC on C18 Vydac column (5 μ M, 100 Å, 10 \times 250 mm) in order to separate the two diastereomers: retention time = 12.85 and 14.35 min (Nucleosil, C18, 150 \times 4.6 mm, 5 μ m, 100 Å, gradient 10–90% B in 30 min, flow rate = 1.5 mL/min).

Both diastereomers were then treated independently by anhydrous hydrogen fluoride³³ with 2% *m*-cresol to yield **21a** (28% yield) and **21b** (20% yield): retention time = 9.6 min (**21a**) and 10.7 min (**21b**) (Nucleosil, C18, 150 \times 4.6 mm, 5 μ m, 100 Å, gradient 10–50% B in 15 min, flow rate = 1.5 mL/min, λ = 214 nm); purity > 99%.

N-[(2*R*,3*S*)-3-Amino-3-(3-sulfamoylphenyl)-2-sulfanylpropanoyl]-L-tyrosyl-N-benzyl-L-histidinamide (21a): retention time = 9.6 min (Nucleosil, C18, 150 \times 4.6 mm, 5 μ m,

100 Å, gradient 10–50% B in 15 min, flow rate = 1.5 mL/min, λ = 214 nm; purity > 99%; ^1H NMR (D_2O + DTT) δ 2.44 (1H, dd, $\beta(\text{Tyr})$), 2.63 (1H, dd, $\beta(\text{Tyr})$), 3.07 (1H, dd, $\beta(\text{His})$), 3.17 (1H, dd, $\beta(\text{His})$), 3.96 (1H, d, CH-SH), 4.19 (1H, t, $\alpha(\text{Tyr})$), 4.20 (1H, d, $\text{CH}_2\text{-C}_6\text{H}_5$), 4.34 (1H, d, $\text{CH}_2\text{-C}_6\text{H}_5$), 4.58 (1H, t, $\alpha(\text{His})$), 4.60 (1H, d, H_2NCH), 6.69 (2H, d, $\text{H}_3\text{-H}_5(\text{Tyr})$), 6.82 (2H, d, $\text{H}_2\text{-H}_6(\text{Tyr})$), 7.14 (1H, s, $\text{H}_4(\text{His})$), 7.19 (2H, d, $\text{H}_2\text{-H}_6(\text{Ar})$), 7.33–7.40 (3H, m, $\text{H}_3\text{-H}_4\text{-H}_5(\text{Ar})$), 7.61 (2H, d, PhSO_2NH_2), 7.84 (1H, s, PhSO_2NH_2), 7.96 (1H, m, PhSO_2NH_2), 8.51 (1H, s, $\text{H}_2(\text{His})$); MS (ESI) ($\text{M} + \text{H}$) $^+$ m/z = 666.2. Anal. ($\text{C}_{31}\text{H}_{35}\text{N}_7\text{O}_6\text{S}_2$).

N-[(2S,3S)-3-Amino-3-(3-sulfamoylphenyl)-2-sulfanylpropanoyl]-L-tyrosyl-N-benzyl-L-histidinamide (21b): retention time = 10.7 min (Nucleosil, C18, 150 \times 4.6 mm, 5 μm , 100 Å, gradient 10–50% B in 15 min, flow rate = 1.5 mL/min, λ = 214 nm); purity > 99%; ^1H NMR (D_2O + DTT) δ 2.88 (2H, m, $\beta(\text{Tyr})$), 3.10 (2H, d, $\beta(\text{His})$), 4.15 (1H, d, $\text{CH}_2\text{-C}_6\text{H}_5$), 4.17 (1H, d, CH-SH), 4.36 (1H, d, $\text{CH}_2\text{-C}_6\text{H}_5$), 4.50 (1H, t, $\alpha(\text{Tyr})$), 4.53 (1H, t, $\alpha(\text{His})$), 5.00 (1H, d, H_2NCH), 6.77 (2H, d, $\text{H}_3\text{-H}_5(\text{Tyr})$), 7.01 (2H, d, $\text{H}_2\text{-H}_6(\text{Tyr})$), 7.14 (1H, s, $\text{H}_4(\text{His})$), 7.16 (2H, d, $\text{H}_2\text{-H}_6(\text{Ar})$), 7.33–7.40 (3H, m, $\text{H}_3\text{-H}_4\text{-H}_5(\text{Ar})$), 7.69 (2H, d, PhSO_2NH_2), 7.88 (1H, s, PhSO_2NH_2), 7.99 (1H, m, PhSO_2NH_2), 8.46 (1H, s, $\text{H}_2(\text{His})$); MS (ESI) ($\text{M} + \text{H}$) $^+$ m/z = 666.2. Anal. ($\text{C}_{31}\text{H}_{35}\text{N}_7\text{O}_6\text{S}_2$).

Both diastereoisomers were synthesized by the procedure described for compounds **21a** and **21b** using synthon C (2SR,3R) (23% yield for **21c** and 19% yield for **21d**).

N-[(2R,3R)-3-Amino-3-(3-sulfamoylphenyl)-2-sulfanylpropanoyl]-L-tyrosyl-N-benzyl-L-histidinamide (21c): retention time = 9.6 min (Nucleosil, C18, 150 \times 4.6 mm, 5 μm , 100 Å, gradient 10–50% B in 15 min, flow rate = 1.5 mL/min, λ = 214 nm); purity > 99%; ^1H NMR (D_2O + DTT) δ 2.78 (1H, ABX, $\beta(\text{Tyr})$), 2.88 (1H, ABX, $\beta(\text{Tyr})$), 2.93 (2H, d, $\beta(\text{His})$), 4.05 (1H, d, CH-SH), 4.10 (1H, d, $\text{CH}_2\text{-C}_6\text{H}_5$), 4.30 (1H, d, $\text{CH}_2\text{-C}_6\text{H}_5$), 4.30 (1H, t, $\alpha(\text{His})$), 4.33 (1H, t, $\alpha(\text{Tyr})$), 4.65 (1H, d, H_2NCH), 6.76 (2H, d, $\text{H}_3\text{-H}_5(\text{Tyr})$), 7.02 (2H, d, $\text{H}_2\text{-H}_6(\text{Tyr})$), 7.07 (1H, s, $\text{H}_4(\text{His})$), 7.12 (2H, d, $\text{H}_2\text{-H}_6(\text{Ar})$), 7.35–7.40 (3H, m, $\text{H}_3\text{-H}_4\text{-H}_5(\text{Ar})$), 7.70 (2H, d, PhSO_2NH_2), 7.86 (1H, t, PhSO_2NH_2), 7.96 (1H, s, PhSO_2NH_2), 8.45 (1H, s, $\text{H}_2(\text{His})$); MS (ESI) ($\text{M} + \text{H}$) $^+$ m/z = 665.7. Anal. ($\text{C}_{31}\text{H}_{35}\text{N}_7\text{O}_6\text{S}_2$).

N-[(2S,3R)-3-Amino-3-(3-sulfamoylphenyl)-2-sulfanylpropanoyl]-L-tyrosyl-N-benzyl-L-histidinamide (21d): retention time = 9.6 min (Nucleosil, C18, 150 \times 4.6 mm, 5 μm , 100 Å, gradient 10–50% B in 15 min, flow rate = 1.5 mL/min, λ = 214 nm); purity > 99%; ^1H NMR (D_2O + DTT) δ 2.75 (2H, m, $\beta(\text{Tyr})$), 3.08 (1H, d, $\beta(\text{His})$), 3.17 (1H, d, $\beta(\text{His})$), 4.11 (1H, d, CH-SH), 4.22 (1H, d, $\text{CH}_2\text{-C}_6\text{H}_5$), 4.35 (1H, d, $\text{CH}_2\text{-C}_6\text{H}_5$), 4.38 (1H, t, $\alpha(\text{Tyr})$), 4.57 (1H, t, $\alpha(\text{His})$), 4.86 (1H, d, H_2NCH), 6.74 (2H, d, $\text{H}_3\text{-H}_5(\text{Tyr})$), 6.94 (2H, d, $\text{H}_2\text{-H}_6(\text{Tyr})$), 7.14 (1H, s, $\text{H}_4(\text{His})$), 7.19 (2H, d, $\text{H}_2\text{-H}_6(\text{Ar})$), 7.34–7.40 (3H, m, $\text{H}_3\text{-H}_4\text{-H}_5(\text{Ar})$), 7.54 (1H, d, PhSO_2NH_2), 7.65 (1H, t, PhSO_2NH_2), 7.87 (1H, s, PhSO_2NH_2), 7.98 (1H, d, PhSO_2NH_2), 8.50 (1H, s, $\text{H}_2(\text{His})$); MS (ESI) ($\text{M} + \text{H}$) $^+$ m/z = 665.6. Anal. ($\text{C}_{31}\text{H}_{35}\text{N}_7\text{O}_6\text{S}_2$).

Acknowledgment. We thank Drs. V. Dive and A. Menez from Département d'ingénierie et d'Etudes des protéines, CEA (Saclay, France), for kindly providing their multiple peptide synthesizer facilities. We are indebted to C. Lenoir for synthesizing the fluorescent substrate required for the enzymatic assay, Emmanuel Ruffet for the determinations of the K_i values of compounds **21a–21d**, and C. Anne for evaluating the kinetics of action of these inhibitors. We also thank Dr. J. R. Cartier from Pasteur-Mérieux for providing the pure TeNt dichain.

References

- Wellhöner, H. H. Tetanus and botulinum neurotoxin. *Handbook of Exp. Pharmacol.* **1992**, 102, 357–417.
- Niemann, H. H. In *Sourcebook of Bacterial Protein Toxins*; Alouf, J. E., Freer, J. H., Eds.; Academic Press: London, 1991; pp 303–348.
- Montecucco, C.; Papini, E.; Schiavo, G. Bacterial protein toxins penetrate cells via a four-step mechanism. *FEBS Lett.* **1994**, 346, 92–98.
- Rawlings, N. D.; Barrett, A. J. Evolutionary families of metallo-peptidases. *Methodol. Enzymol.* **1995**, 248, 183–228.
- Lipscomb, W. N.; Sträter, N. Recent advances in zinc enzymology. *Chem. Rev.* **1996**, 96, 2375–2433.
- Roques, B. P.; Noble, F.; Dauge, V.; Fournié-Zaluski, M.-C.; Beaumont, A. Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. *Pharmacol. Rev.* **1993**, 45 (1), 87–146.
- Matthews, B. Structural Basis of the Action of Thermolysin and Related Zinc Peptidase. *Acc. Chem. Res.* **1988**, 21, 333–340.
- Li, Y.; Foran, P.; Fairweather, N. F.; de Paiva, A.; Weller, U.; Dougan, G.; Dolly, J. O. A single mutation in the recombinant light chain of tetanus toxin abolishes its proteolytic activity and removes the toxicity seen after reconstitution with native heavy chain. *Biochemistry* **1994**, 33, 7014–7020.
- Yamasaki, S.; Hu, Y.; Binz, T.; Kalkuhl, A.; Kurazono, H.; Tamura, T.; Jahn, R.; Kandel, E.; Niemann, H. Synaptobrevin/vesicle-associated membrane protein (VAMP) of *Aplysia californica*: structure and proteolysis by tetanus toxin and botulinum neurotoxins type D and F. *Proc. Natl. Acad. Sci. U.S.A.* **1994**, 91 (11), 4688–4692.
- Borden Lacy, D.; Tepp, W.; Cohen, A. C.; DasGupta, B. R.; Stevens, R. C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. *Nature Struct. Biol.* **1998**, 5, 898–902.
- Schiavo, G.; Benfenati, F.; Poulain, B.; Rossetto, O.; Polverino de Laureto, P.; DasGupta, B.; Montecucco, C. Tetanus and Botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. *Nature* **1992**, 359 (6398), 832–835.
- Trimble, W. S.; Cowan, D. M.; Scheller, R. H. VAMP-1: a synaptic vesicle-associated membrane protein. *Proc. Natl. Acad. Sci. U.S.A.* **1988**, 85, 4538–4542.
- Baumert, M.; Maycox, P. R.; Navone, F.; De Camilli, P.; Jahn, R. Synaptobrevin: an integral membrane protein present in small synaptic vesicles of rat brain. *EMBO J.* **1989**, 8, 379–384.
- Südhof, T. C.; Baumert, M.; Perin, M. S.; Jahn, R. A. A synaptic vesicle membrane protein is conserved from mammals to chophila. *Neuron* **1989**, 2, 1475–1481.
- Rossetto, O.; Schiavo, G.; Montecucco, C.; Poulain, B.; Deloye, F.; Lozzi, L.; Shone, C. Snare motifs and neurotoxin. *Nature* **1994**, 372, 415–416.
- Cornille, F.; Martin, L.; Lenoir, C.; Cussac, D.; Roques, B. P.; Fournié-Zaluski, M.-C. Cooperative Exosite-dependent Cleavage of Synaptobrevin by Tetanus Toxin Light Chain. *J. Biol. Chem.* **1997**, 272 (6), 3459–3464.
- Pellizari, R.; Rossetto, O.; Lozzi, L.; Giovedi, S.; Johnson, E.; Shone, C. C.; Montecucco, C. Structural determinants of the specificity for synaptic vesicle-associated membrane protein/synaptobrevin of tetanus and botulinum type B and G neurotoxins. *J. Biol. Chem.* **1996**, 271, 20353–20358.
- Foran, P.; Shone, C. C.; Dolly, J. O. Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments. *Biochemistry* **1994**, 33, 15365–15374.
- Cornille, F.; Goudreau, N.; Flicheux, D.; Niemann, H.; Roques, B. P. Solid-phase synthesis, conformational analysis and in vitro cleavage of synthetic human synaptobrevin II 1–93 by tetanus toxin L chain. *Eur. J. Biochem.* **1994**, 222 (1), 173–181.
- Sanders, D.; Habermann, E. Evidence for a link between specific proteolysis and inhibition of $[\text{H}^+]$ -noradrenaline release by the light chain of tetanus toxin. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **1992**, 346 (3), 358–361.
- Schiavo, G.; Poulain, B.; Rossetto, O.; Benfenati, F.; Tauc, L.; Montecucco, C. Tetanus toxin is a zinc protein and its inhibition of neurotransmitter release and protease activity depend on zinc. *EMBO J.* **11**, 3577–3583.
- Martin, L.; Coric, P.; Cornille, F.; Roques, B. P.; Fournié-Zaluski, M.-C. β -Amino thiols inhibit the Zn-metalloproteinase activity of tetanus toxin light chain. *J. Med. Chem.* **1998**, 41, 3450–3460.
- Gordon, E. M.; Godfrey, J. D.; Delaney, N. G.; Asaad, M. M.; Von Langen, D.; Cushman, D. W. Design of novel inhibitors of aminopeptidases. Synthesis of peptide-derived diamino thiols and sulfur replacement analogues of bestatin. *J. Med. Chem.* **1988**, 31, 2199–2211.
- Bischoff, L.; David, C.; Martin, L.; Meudal, H.; Roques, B. P.; Fournié-Zaluski, M.-C. 2,4-Dinitrophenyl 4-methoxybenzyl disulfide: a new efficient reagent for the electrophilic sulfenylation of β -amino ester enolates. *J. Org. Chem.* **1997**, 62, 4848–4850.
- Brown, W. G. Reductions by lithium aluminum hydride. *Org. React.* **1951**, 6, 469–509.
- Mancuso, A. J.; Swern, D. Activated dimethyl sulfoxide: useful reagents for synthesis. *Synthesis* **1981**, 165–184.
- Wadsworth, W. S.; Emmons, W. D. The utility of phosphonate carbanions in olefin synthesis. *J. Am. Chem. Soc.* **1961**, 83, 1733–1738.

- (28) Davies, S. G.; Ichihara, O. Asymmetric synthesis of *R*- β -amino butanoic acid and *S*- β -tyrosine: homochiral lithium amide equivalents for Michael additions to α,β -unsaturated esters. *Tetrahedron: Asym.* **1991**, *2* (3), 183–186.
- (29) Burke, A. J.; Davies, S. G.; Hedgecock, C. J. R. Asymmetric synthesis of (2*S*,3*S*)- and (2*R*,3*S*)-2,3-diaminobutanoic acids, nonprotein amino acid diastereomers found in a number of peptide antibiotics. *Synlett* **1996**, 621–622.
- (30) Shibata, N.; Baldwin, J. E.; Jacobs, A.; Wood, M. E. Electrophilic sulfenylation in a stereocontrolled synthesis of protected (2*R*,3*R*)-3-mercaptoaspartic acid from L-aspartic acid. *Tetrahedron* **1996**, *52* (39), 12839–12852.
- (31) Lu, G.-S.; Mojsos, S.; Tam, J. P.; Merrifield, R. B. Improved Synthesis of 4-Alkoxybenzyl Alcohol Resin. *J. Org. Chem.* **1981**, *46*, 3433–3436.
- (32) Pearson, D. A.; Blanchette, M.; Baker, M.; Guindon, C. A. Trialkylsilanes as scavengers for the trifluoroacetic acid de-blocking of protecting groups in peptide synthesis. *Tetrahedron Lett.* **1989**, *30* (21), 2739–2742.
- (33) Sakakibara, S.; Shimonishi, Y.; Kishida, Y.; Okada, M.; Sugihara, H. Use of anhydrous hydrogen fluoride in peptide synthesis. I. Behavior of various protective groups in anhydrous hydrogen fluoride. *Bull. Chem. Soc. Jpn.* **1967**, *40* (9), 2164–2167.
- (34) Barlos, K.; Chatzi, O.; Gatos, D.; Stravropoulos, G. 2-Chlorotriptyl chloride resin. *Int. J. Pept. Protein Res.* **1991**, *37*, 513–520.
- (35) Jiracek, J.; Yiotakis, A.; Vincent, B.; Lecoq, A.; Nicolaou, A.; Checler, F.; Dive, V. Development of highly potent and selective phosphonic peptide inhibitors of zinc endopeptidase 24–15 using combinatorial chemistry. *J. Biol. Chem.* **1995**, *270* (37), 21701–21706.
- (36) Jiracek, J.; Yiotakis, A.; Vincent, B.; Checler, F.; Dive, V. Development of the first potent and selective inhibitor of the zinc endopeptidase neurolysin using a systematic approach based on combinatorial chemistry of phosphinic peptides. *J. Biol. Chem.* **1996**, *271* (32), 19606–19611.
- (37) Furka, A.; Sebestyen, F.; Asgedom, M.; Dibo, G. General method for rapid synthesis of multicomponent peptide mixtures. *Int. J. Pept. Protein Res.* **1991**, *37*, 487–493.
- (38) Barlos, K.; Gatos, D.; Kutsogianni, S.; Papaphotiou, G.; Poulos, C.; Tsegenidis, T. Solid phase synthesis of partially protected and free peptides containing disulphide bonds by simultaneous cysteine oxidation-release from 2-chlorotriptyl resin. *Int. J. Pept. Protein Res.* **1991**, *38*, 562–568.
- (39) Soleilhac, J.-M.; Cornille, F.; Martin, L.; Lenoir, C.; Fournié-Zaluski, M.-C.; Roques, B. P. A Sensitive and Rapid Fluorescence-Based Assay for Determination of Tetanus Toxin Peptidase Activity. *Anal. Biochem.* **1996**, *241*, 120–127.
- (40) Ellman, J. A.; Gallop, M. A. Combinatorial chemistry. *Curr. Opin. Chem. Biol.* **1998**, *2*, 317–319.
- (41) Gallop, M. A.; Barrett, R. W.; Dower, W. J.; Fodor, S. P.; Gordon, E. M. Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries. *J. Med. Chem.* **1994**, *37*, 1233–1251.
- (42) Gallop, M. A.; Barrett, R. W.; Dower, W. J.; Fodor, S. P.; Gordon, E. M. Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions. *J. Med. Chem.* **1994**, *37*, 1385–1401.
- (43) Kuntz, I. D. Structure-based strategies for design and discovery. *Science* **1992**, *257*, 1078–1082.
- (44) Lybrand, T. P. Ligand-protein docking and rational drug design. *Curr. Opin. Struct. Biol.* **5**, 224–228.
- (45) Murphy, M. M.; Schullek, J. R.; Gordon, E. M.; Gallop, M. A. Combinatorial organic synthesis of highly functionalized pyrolidines: identification of a potent angiotensin converting enzyme inhibitor from a mercaptoacyl proline library. *J. Am. Chem. Soc.* **1995**, *117*, 7029–7030.
- (46) Rockwell, A.; Melden, M.; Copeland, R. A.; Hardman, K.; Decicco, C. P.; DeGrado, W. F. Complementarity of combinatorial chemistry and structure-based ligand design: Application to the discovery of novel inhibitors of matrix metalloproteinases. *J. Am. Chem. Soc.* **1996**, *118*, 10337–10338.
- (47) Wyvratt, M. J.; Patchett, A. A. Recent developments in the design of angiotensin-converting enzyme inhibitors. *Med. Res. Rev.* **1985**, *5* (4), 483–531.
- (48) Chauvel, E. N.; Coric, P.; Llorens-Cortes, C.; Wilk, S.; Roques, B. P.; Fournié-Zaluski, M.-C. Investigation of the active site of aminopeptidase A using a series of new thiol-containing inhibitors. *J. Med. Chem.* **1994**, *37*, 1339–1346.
- (49) Yamasaki, S.; Baumeister, A.; Binz, T.; Blasi, J.; Link, E.; Cornille, F.; Roques, B. P.; Fykse, E.; Südhof, T.; Jahn, R. Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinum neurotoxins and tetanus toxin. *J. Biol. Chem.* **1994**, *269*, 12764–12772.
- (50) Castro, B.; Dormoy, J. R.; Evin, G.; Selve, C. Réactifs de couplage peptidique IV (1) – L'hexafluorophosphate de benzotriazolyl n-oxytrisdiméthylamino phosphonium (B.O.P.). *Tetrahedron Lett.* **1975**, *14*, 1219–1222.
- (51) Bunnage, M. E.; Davies, S. G.; Goodwin, C. J.; Ichihara, O. An expeditious asymmetric synthesis of allophenylnorstatine. *Tetrahedron* **1994**, *50* (13), 3975–3986.

JM981066W